RXRB and atrial fibrillation: Moreover, per 1 SD decrement in HbA1c via targeting RXRB of thiazolidinediones (TZDs) was found to be markedly related to a lowered incidence of AF (OR: 0.88, 95% CI: 0.82, 0.94, PFDR = 0.017) (Figures 2B and 3).